OrthoAccel Technologies has announced an equity investment of $10 million in growth capital to fund the U.S. launch of its AcceleDent system.
The investment was led by HealthpointCapital Partners, with existing investor S3 Ventures also participating, according to a company press release.
AcceleDent is designed to reduce treatment time for wearing braces and works as a complement to all existing orthodontic technologies, including both brackets and clear aligners.
The product was introduced to the U.K., Australia, France, Italy, and approximately a dozen other countries in the last two years. In November, OrthoAccel received U.S. Food and Drug Administration 510(k) approval to sell in the U.S.
The company will formally launch the AcceleDent system this month at the American Association of Orthodontists annual conference in Honolulu, HI.
